抗肿瘤血管生成靶向药物的不良反应、发生机制及处理

通过抑制新生血管以达到控制肿瘤是目前抗肿瘤治疗的重要研究方向,抗肿瘤血管生成靶向药物在临床肿瘤治疗中已广泛应用,包括贝伐单抗、重组人血管内皮抑素以及多靶点激酶抑制剂索拉非尼、舒尼替尼等,药物不良反应包括高血压、心脏毒性、血栓形成、出血、蛋白尿、胃肠道穿孔、伤口愈合不良以及索拉非尼和舒尼替尼较常见的疲乏、腹泻、手足综合征等,多数不良反应为1及或2级,患者耐受性及依从性较好.

Adverse effects, pathogenesis and treatment of anti-angiogenetic targeting agents

Tumor growth is dependent on angiogenesis.At present,antiangiogenic treatment has been one of the most studied and exploited targets for molecular cancer therapy.Up to date,anti-angiogenesis drugs,which has already been applicated in clinic widely,include bevacizumab,endostar,multi-target tyrosine kinase inhibitor such as sorafenib and sunitinib.The main adverse effects associated with antiangiogenic therapy include hypertension,cardiotoxicity,thrombosis,bleeding,proteinuria,impaired wound healing,gastrointestinal perforation,lassitude,diarrhoea,hand foot shin response,etc,the later three is common in sorafenib and sunitinib.The majority of adverse effects are generally mild to moderate in severity and tolerated by patients.although there are specific,uncommon events that are severe and can be lifethreatening.